The global gastroenterology market is entering a decisive growth phase, shaped by an unprecedented disease burden and rapid technological transformation. In 2025 alone, more than 1.1 billion people worldwide are affected by GI disorders, while over 112 million endoscopic procedures are performed annually—a figure climbing steadily as colorectal cancer screening expands. Valued at roughly $60 billion in 2025 and projected to exceed $100 billion by 2033, the industry is being propelled by rising GERD, IBS, IBD, and colorectal cancer cases, alongside strong hospital investment in minimally invasive diagnostics and therapies. Major markets such as the U.S., Japan, Europe, China, and India continue to dominate, but emerging regions are accelerating adoption as infrastructure and screening programs mature.
What truly sets this era apart is technology. AI-assisted endoscopy is already improving adenoma detection rates by up to 18%, capsule endoscopy usage is surging due to its non-invasive appeal, and hospitals are rapidly upgrading to 4K/8K imaging, robotic platforms, and cloud-based GI workflows. The ecosystem now spans over 2,500 device manufacturers, 180+ GI-focused pharma companies, and a fast-growing digital health layer powering tele-gastroenterology and AI-driven documentation. As biologics, precision diagnostics, and software-defined GI care converge, gastroenterology is evolving from a procedure-driven specialty into a data- and technology-led clinical frontier—reshaping how digestive diseases are detected, treated, and managed globally.